The news that "the world's first inactivated COVID-19 vaccine production workshop has passed the national biosafety inspection" has attracted attention.

China National Pharmaceutical Group Corporation8Month5On the day of disclosure, the COVID-19 inactivated vaccine production workshop of the Beijing Institute of Biological Products has passed the biosafety joint inspection organized by relevant national departments and is ready for use. Previously, this production facility had also just obtained the production license for the COVID-19 vaccine.

The recently inspected high-level biosafety production facility in Beijing is currently the world's first and largest inactivated COVID-19 vaccine production workshop.

The Beijing Institute of Biological Products completed the construction of the workshop in just2months, achieving the "Huoshenshan" speed for the construction of the COVID-19 inactivated vaccine workshop.4Month15On the day of completion, it created the "Huoshenshan" speed for the construction of the COVID-19 inactivated vaccine workshop.

China National Pharmaceutical Group has built high-level biosafety production facilities at both the Beijing and Wuhan biological product research institutes.

After the production workshops of these two research institutes are put into use, China National Pharmaceutical will be able to ensure a total annual production capacity of2.2hundred million doses.

The Wuhan Institute of Biological Products and the Beijing Institute of Biological Products' COVID-19 inactivated vaccine

vaccine research and development, China is leading globally.

Currently, multiple teams, including the scientific research leadership group led by Yang Xiaoming of China National Pharmaceutical Group and the team of Academician Chen Wei from the Academy of Military Medical Sciences, have entered the clinical trial stage for COVID-19 vaccines, making China the country with the most significant achievements in the global research and development of COVID-19 vaccines.

The inactivated vaccine developed by China National Pharmaceutical Group has now entered the third phase of clinical trials and has the capacity for large-scale mass production, with all progress being at the global leading level.

Yang Xiaoming, chairman of China National Pharmaceutical Group, stated in an exclusive interview with reporters that it is optimistically estimated that the domestically produced inactivated COVID-19 vaccine may be available by the end of this year or early next year.

Netizens are eagerly discussing: Looking forward to the day we can get vaccinated!

Extended reading

Let's take a look at

the original message released by China National Pharmaceutical Group.

Recently, the COVID-19 inactivated vaccine production workshop of the Beijing Institute of Biological Products of China National Pharmaceutical Group passed the biosafety joint inspection organized by relevant national departments and is ready for use. Previously, this production facility had obtained the production license for the COVID-19 vaccine.

In the fight against the COVID-19 pandemic, China National Pharmaceutical Group has earnestly implemented General Secretary Xi Jinping's important instructions on providing technological support for epidemic prevention and control, prioritizing the maintenance of national public health safety and people's life and health, and launching a comprehensive attack on diagnosis, treatment, and prevention, achieving a series of globally leading innovative results marked by rapid portable nucleic acid testing kits, convalescent plasma treatment methods, COVID-specific immunoglobulin, and inactivated COVID-19 vaccines. While vigorously promoting vaccine research and development, China National Pharmaceutical Group has taken proactive measures, playing a leading role as an enterprise, and has built high-level biosafety production facilities at both the Beijing and Wuhan biological product research institutes.

The recently inspected high-level biosafety production facility in Beijing is currently the world's first and largest inactivated COVID-19 vaccine production workshop. China National Pharmaceutical Group and China Biological attach great importance to the construction of this workshop, adhering to the concept of "safety first" throughout the design, construction, and use process, following relevant biosafety norms and standards from national and World Health Organization guidelines, introducing experienced design teams from both domestic and international sources, and drawing on advanced international experiences to construct and manage according to biosafety level three protection standards. With strong support from the Beijing municipal government, the Beijing Institute of Biological Products completed the construction in just2months, achieving the "Huoshenshan" speed for the construction of the COVID-19 inactivated vaccine workshop.4Month15On the day of completion, it created the "Huoshenshan" speed for the construction of the COVID-19 inactivated vaccine workshop.7mid-month, and relevant national departments organized experts to conduct a comprehensive inspection of the biosafety of the COVID-19 vaccine production workshop at the Beijing Institute of Biological Products, concluding that the production workshop basically meets national standards and can be put into large-scale production of the COVID-19 vaccine.

The high-level biosafety facility and supporting laboratory complex of the Wuhan Institute of Biological Products was completed on7Month1day, and7by the end of the month, it will reach the conditions for delivery and use, striving to obtain relevant inspections and meet production conditions as soon as possible. The Wuhan Institute of Biological Products will also become the only biological product research and production unit in the world with a high-level biosafety research laboratory and production facility complex. After the production workshops of the two research institutes are put into use, China National Pharmaceutical will be able to ensure a total annual production capacity of2.2hundred million doses.

The completion of the COVID-19 inactivated vaccine production workshop fills the gap in domestic hardware infrastructure. At the same time, in cooperation with relevant departments, the first vaccine biosafety production facility standards and biosafety system documents have been compiled, filling the gap in China's hardware standards and management systems for high-level biosafety workshops for human vaccines. The completion and use of the workshop provide a safe and reliable hardware guarantee for the current large-scale production of vaccines and for ensuring vaccine research and development efficiency and production capacity in the event of a major infectious disease outbreak in the future.

China National Pharmaceutical Group will strictly manage the biosafety of production facilities according to General Secretary Xi Jinping's requirements, enforce strict quality control throughout the vaccine research and production process, and do everything possible to ensure the safety, effectiveness, and accessibility of the inactivated COVID-19 vaccine, contributing to epidemic prevention and control in China and globally.